David Hutton

According to the company, its partnership will educate the gaming community on common dry eye symptoms and introduce over-the-counter options like its Systane brand of eye drops.

RightEye Sensorimotor is a new technology designed to greatly improve patient care and increase optometry and ophthalmology practice revenue.

Michael Rivers, MD, discusses the impact of Aetna's new policy requiring prior authorization for cataract surgery on ophthalmologists, their workflow, and patients.

The American Academy of Ophthalmology issued a guidance this week requiring all in-person attendees at its annual meeting Nov. 12-15 in New Orleans to show proof of COVID-19 vaccination.

Science fiction is quickly becoming science fact as a team of German scientists has developed a small, lab-grown brain cell cluster that developed fundamental eye structures.

A survey by Health Union sheds light on the issues patients are facing and can help ophthalmologists map out dry eye disease treatment strategies.

The American Society of Retina Specialists is gearing up for its 39th annual scientific meeting Oct. 8-12 at the JW Marriott San Antonio Hill Country Resort and Spa in San Antonio, Texas.

Michael Rivers, MD, discusses how Modernizing Medicine's latest updates to its electronic health records EMA® system benefits both ophthalmologists and optometrists.

The Academy has stepped up to speak out against the use of untested biosimilars in the eyes of patients amid a disruption in the drug supply chain.

Aequus Pharmaceuticals, reVision Therapeutics announced this week that they will collaborate to develop a therapy for Stargardt disease.

Oxurion is currently recruiting patients for the Phase 2 clinical study of THR-687 in DME.

Michael Rivers, MD, discusses the impact of Aetna's new policy requiring prior authorization for cataract surgery on ophthalmologists, their workflow, and patients.

Edward Holland, MD, discusses Aurion Biotech's investigation of an injectable technique where one cornea donor could potentially supply hundreds of patients with treatment for endothelial disease.

The Research to Prevent Blindness (RPB), the Association of University Professors of Ophthalmology (AUPO) and an anonymous donor have recognized Donald Zack, MD, PhD, for ground-breaking contributions to the field of vision research.

According to Oculus, its Myopia Master saves space and can be mounted on a workstation or an ophthalmic table. The software is operated directly via an inbuilt display.

The company is evaluating topical cyclosporine to treat the signs and symptoms of dry eye disease.

pVerify's Vision Benefits API allows front-office staff to handle vision eligibility verifications seamlessly in their own EHR.

Edward Manche, MD, discusses results from his presentation regarding outcomes of corneal crosslinking keratoconus in a pediatric population.

Ed Hu, MD, PhD, shares highlights from his paper analyzing three years' worth of his own postop data on comparative lens rotations in toric IOL platforms.

Outlook Therapeutics has reported positive efficacy and safety data from Phase 3 NORSE TWO trial of bevacizumab-vikg.

The organization hopes to help 1 billion people worldwide, committing the international community to improve vision for 1.1 billion people living with preventable vision loss by 2030.

Investigators uncovered evidence that CaMKII could prove to be a desirable therapeutic target for vision preservation in conditions that damage the axons and somas of retinal ganglion cells.

A team of investigators used corneal confocal microscopy to identify corneal nerve damage in cases of long COVID.

Mitch Shultz, MD, speaks on the capabilities of a cloud-based database system to look at energy-fluid metrics, provide surgeons with the capacity to refine procedures and give patients better outcomes.

Colman R. Kraff, MD, shares highlights of a study evaluating the safety and efficacy of the use of the iDesign 2.0 Refractive Studio for the treatment of patients with hyperopia and myopia.

Chuck Hess shares an update on Bausch + Lomb's latest developments in surgical technology, as well as how the company has adapted its operations during the pandemic.

Jag Dosanjh, senior vice president of U.S. Eye Care, Allergan, an AbbVie company, offers a preview of the company's latest innovations, developments, and what attendees can look forward to at ASCRS 2021.

AAO, Surgical Care Coalition teaming up to ensure the final version of the rule is fair to ophthalmologists and surgeons as one company is expressing its disappointment in the proposal.

Nanoscope Therapeutics Inc. has dosed its first patient in a late-stage Phase 2b trial of a gene therapy that delivers multi-characteristic opsin to retinal cells.